193
Views
9
CrossRef citations to date
0
Altmetric
Article

POSTTRANSPLANT ORAL IRON-CHELATING THERAPY IN PATIENTS WITH β-THALASSEMIA MAJOR

, MD, , MD, , MD, , MD &
Pages 374-379 | Accepted 26 Feb 2010, Published online: 06 Jul 2010

REFERENCES

  • Lucarelli G, Gaziev D. Advances in the allogeneic transplantation for thalassemia. Blood Rev. 2008;22:53–63.
  • Lucarelli G, Angelucci E, Giardini C, . Fate of iron stores in thalassemia after bone marrow transplantation. Lancet. 1993;342:417–421.
  • Angelucci E, Muretto P, Lucarelli G, . Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Blood. 1997;90:994–998.
  • Giardini C, Galimberti M, Lucarelli G, . Desferrioxamine therapy accelerates clearance of iron deposits after bone marrow transplantation for thalassemia. Br J Haematol. 1995;89:868–873.
  • Lucarelli G, Galimberti M, Polchi P, . Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322:417–421.
  • Majhail NS, Lazarus HM, Burns LJ. Iron overload in hematopetic cell transplantation. Bone Marrow Transplant. 2008;41:997–1003.
  • Jastaniah W, Harmatz P, Pakbaz Z, . Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr Blood Cancer. 2008;50:319–324.
  • Mariotti E, Angelucci E, Agostini A, . Evaluation of cardiac status in iron-loaded thalassemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol. 1998;103:916–921.
  • Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med. 2002;136:667–672.
  • Telfer PT, Prescott E, Holden S, . Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassemia major. Br J Haematol. 2000;110; 971–977.
  • Shalitin S, Carmi D, Weintrob N, . Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. Eur J Haematol. 2005;74:93–100.
  • Cappellini MD, Cohen A, Piga A, . A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–3462.
  • Vichinsky E, Onyekwere O, Porter J, . A randomized comparison of deferasirox versus deferroxamine for the treatment of transfusional iron overload in sickle cell anemia. Br J Haematol. 2007;136:501–508.
  • Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol. 2008;83:398–402.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.